| scholarly article | Q13442814 |
| P2093 | author name string | Hajnalka Rajnai | |
| Anna Sebestyén | |||
| Judit Pápay | |||
| Titanilla Dankó | |||
| András Jeney | |||
| Gábor Petővári | |||
| Ildikó Krencz | |||
| Zoltán Hujber | |||
| Enikő Vetlényi | |||
| Regina Raffay | |||
| P2860 | cites work | Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment | Q91533597 |
| Mammalian Target of Rapamycin 2 (MTOR2) and C-MYC Modulate Glucosamine-6-Phosphate Synthesis in Glioblastoma (GBM) Cells Through Glutamine: Fructose-6-Phosphate Aminotransferase 1 (GFAT1) | Q91639807 | ||
| Gboxin is an oxidative phosphorylation inhibitor that targets glioblastoma | Q92179854 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Chloroquine activates the p53 pathway and induces apoptosis in human glioma cells | Q24607826 | ||
| Alternative fuels for cancer cells | Q26997591 | ||
| Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells | Q33759313 | ||
| Valproic acid downregulates the expression of MGMT and sensitizes temozolomide-resistant glioma cells | Q36026945 | ||
| Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma | Q36544101 | ||
| Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma | Q36650859 | ||
| Temozolomide promotes genomic and phenotypic changes in glioblastoma cells. | Q36875981 | ||
| Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma | Q38284095 | ||
| Targeting the PI3K/AKT/mTOR Pathway for the Treatment of Mesenchymal Triple-Negative Breast Cancer: Evidence From a Phase 1 Trial of mTOR Inhibition in Combination With Liposomal Doxorubicin and Bevacizumab | Q38377100 | ||
| Metabolic reprogramming in glioblastoma: the influence of cancer metabolism on epigenetics and unanswered questions | Q38548208 | ||
| Molecular and Microenvironmental Determinants of Glioma Stem-Like Cell Survival and Invasion | Q38697415 | ||
| The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary | Q38829244 | ||
| mTORC1 and mTORC2 in cancer and the tumor microenvironment | Q38982579 | ||
| Expression of mTORC1/2-related proteins in primary and brain metastatic lung adenocarcinoma | Q39063542 | ||
| Mitochondria and cancer chemoresistance | Q39119820 | ||
| Multidrug resistance in glioblastoma stem-like cells: Role of the hypoxic microenvironment and adenosine signaling | Q39145672 | ||
| Functional Subclone Profiling for Prediction of Treatment-Induced Intratumor Population Shifts and Discovery of Rational Drug Combinations in Human Glioblastoma | Q39493324 | ||
| Clonal evolution of glioblastoma under therapy. | Q39704836 | ||
| Fatty acid oxidation is required for the respiration and proliferation of malignant glioma cells | Q40067927 | ||
| High LC3/Beclin Expression Correlates with Poor Survival in Glioma: a Definitive Role for Autophagy as Evidenced by In Vitro Autophagic Flux | Q47664663 | ||
| The Pro-tumorigenic Effects of Metabolic Alterations in Glioblastoma Including Brain Tumor Initiating Cells | Q47834398 | ||
| Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy. | Q47903730 | ||
| Enhanced glioma therapy by synergistic inhibition of autophagy and tyrosine kinase activity | Q48121201 | ||
| Brain Tumor Stem Cells Remain in Play | Q48228839 | ||
| Radiogenomics to characterize regional genetic heterogeneity in glioblastoma | Q48582092 | ||
| Glutamine Transport and Mitochondrial Metabolism in Cancer Cell Growth. | Q49627330 | ||
| The carnitine system and cancer metabolic plasticity. | Q51769132 | ||
| mTOR Signaling in Growth, Metabolism, and Disease. | Q54144950 | ||
| A Critical Overview of Targeted Therapies for Glioblastoma | Q58122179 | ||
| Doxycycline, an Inhibitor of Mitochondrial Biogenesis, Effectively Reduces Cancer Stem Cells (CSCs) in Early Breast Cancer Patients: A Clinical Pilot Study | Q58569832 | ||
| Targeting cellular metabolism using rapamycin and/or doxycycline enhances anti-tumour effects in human glioma cells | Q60043947 | ||
| Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities | Q61800092 | ||
| Diverse signaling mechanisms of mTOR complexes: mTORC1 and mTORC2 in forming a formidable relationship | Q90211517 | ||
| Metabolic reprogramming in the pathogenesis of glioma: Update | Q90881586 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 23-33 | |
| P577 | publication date | 2019-06-11 | |
| P1433 | published in | Pathology Oncology Research | Q26842743 |
| P1476 | title | Inhibition of Metabolic Shift can Decrease Therapy Resistance in Human High-Grade Glioma Cells | |
| P478 | volume | 26 |
Search more.